T Rau

Summary

Affiliation: University of Hamburg
Country: Germany

Publications

  1. doi request reprint Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study
    T Rau
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Pharmacol Ther 85:269-72. 2009
  2. ncbi request reprint High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations
    Thomas Rau
    Department of Clinical and Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, and Children s Hospital, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacol Ther 80:468-76. 2006
  3. ncbi request reprint CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study
    Thomas Rau
    Department of Pharmacology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Pharmacol Ther 75:386-93. 2004
  4. ncbi request reprint [Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers]
    H Wuttke
    Institut fur Experimentelle und Klinische Pharmakologie, Universitatsklinikum Hamburg Eppendorf, Hamburg
    Dtsch Med Wochenschr 129:831-5. 2004
  5. pmc P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease
    Anneke Bierend
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Br J Clin Pharmacol 65:540-7. 2008
  6. ncbi request reprint The 2988G>A polymorphism affects splicing of a CYP2D6 minigene
    Thomas Rau
    Clin Pharmacol Ther 80:555-8; author reply 558-60. 2006
  7. ncbi request reprint Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment
    Thomas Rau
    Institute of Clinical and Experimental Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Fahrstr 17, 91054 Erlangen, Germany
    Pharmacogenetics 12:465-72. 2002
  8. ncbi request reprint Association of progesterone receptor polymorphism with recurrent abortions
    Andreas Schweikert
    Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, University of Erlangen Nurnberg, Universitätsstrasse 21 23, 91054 Erlangen, Germany
    Eur J Obstet Gynecol Reprod Biol 113:67-72. 2004
  9. ncbi request reprint Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
    Ulrike Werner
    Department of Experimental and Clinical pharmacology and Toxicology and II Medical Clinic, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacol Ther 74:130-7. 2003
  10. ncbi request reprint Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects
    Henrike Wuttke
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Germany
    Clin Pharmacol Ther 72:429-37. 2002

Collaborators

Detail Information

Publications16

  1. doi request reprint Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study
    T Rau
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Pharmacol Ther 85:269-72. 2009
    ..It appears, therefore, that the CYP2D6 genotype contributes to interindividual differences in metoprolol response...
  2. ncbi request reprint High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations
    Thomas Rau
    Department of Clinical and Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, and Children s Hospital, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacol Ther 80:468-76. 2006
    ..We hypothesized that common genetic variations may contribute to the variability of high-dose methotrexate pharmacokinetics...
  3. ncbi request reprint CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study
    Thomas Rau
    Department of Pharmacology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Pharmacol Ther 75:386-93. 2004
    ....
  4. ncbi request reprint [Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers]
    H Wuttke
    Institut fur Experimentelle und Klinische Pharmakologie, Universitatsklinikum Hamburg Eppendorf, Hamburg
    Dtsch Med Wochenschr 129:831-5. 2004
  5. pmc P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease
    Anneke Bierend
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Br J Clin Pharmacol 65:540-7. 2008
    ....
  6. ncbi request reprint The 2988G>A polymorphism affects splicing of a CYP2D6 minigene
    Thomas Rau
    Clin Pharmacol Ther 80:555-8; author reply 558-60. 2006
  7. ncbi request reprint Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment
    Thomas Rau
    Institute of Clinical and Experimental Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Fahrstr 17, 91054 Erlangen, Germany
    Pharmacogenetics 12:465-72. 2002
    ..01). In summary, the pronounced effect of the CYP2D6 genotype persists during long-term therapy, affecting both metabolic ratio and metoprolol plasma concentration...
  8. ncbi request reprint Association of progesterone receptor polymorphism with recurrent abortions
    Andreas Schweikert
    Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, University of Erlangen Nurnberg, Universitätsstrasse 21 23, 91054 Erlangen, Germany
    Eur J Obstet Gynecol Reprod Biol 113:67-72. 2004
    ..The current study sought for polymorphisms within the progesterone receptor (PR) gene. Allele and genotype frequencies of patients with repeated abortions were compared to a control group...
  9. ncbi request reprint Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
    Ulrike Werner
    Department of Experimental and Clinical pharmacology and Toxicology and II Medical Clinic, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacol Ther 74:130-7. 2003
    ..Therefore the objective of this study was to examine the effect of celecoxib and rofecoxib on the pharmacokinetics of the clinically relevant CYP2D6 substrate metoprolol...
  10. ncbi request reprint Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects
    Henrike Wuttke
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Germany
    Clin Pharmacol Ther 72:429-37. 2002
    ..This study addressed whether the incidence of poor metabolizers was higher in patients with metoprolol-associated adverse effects than in the German population at large...
  11. ncbi request reprint Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac
    Burkhard Hinz
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacol Ther 74:222-35. 2003
    ..This study investigated whether biotransformation to metabolites (4'-hydroxy-aceclofenac, diclofenac, 4'-hydroxy-diclofenac) contributes to inhibitory effects on the cyclooxygenase (COX) isozymes in vitro and ex vivo...
  12. ncbi request reprint Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells
    Birthe Willipinski-Stapelfeldt
    Institute of Tumor Biology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 11:8006-14. 2005
    ..Here, we aimed to profile the protein expression of these cells using unique cell line models and to evaluate the prognostic relevance of candidate gene expression for breast cancer patients...
  13. ncbi request reprint Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not
    Cordula Meyer zu Schwabedissen
    Interdisciplinary Intermediate Care, University Hospital of Aachen, RWTH Aachen, 52057 Aachen, Germany
    Eur J Clin Pharmacol 62:713-20. 2006
    ..Initiation of phenprocoumon therapy is associated with a variable individual response. The CYP2C9 genotype has been shown to influence the response to warfarin therapy, but such an effect on phenprocoumon therapy remains uncertain...
  14. ncbi request reprint Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography
    Burkhard Hinz
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nurnberg, Fahrstrasse 17, D 91054 Erlangen, Germany
    Biomed Chromatogr 17:268-75. 2003
    ..The developed procedure was applied to assess the pharmacokinetics of aceclofenac and its metabolites following administration of a single 100 mg oral dose of aceclofenac to three healthy male volunteers...
  15. doi request reprint Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment
    Jens Kollermann
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 26:4928-33. 2008
    ..To explore whether the presence of occult disseminated tumor cells (DTCs) in the bone marrow before neoadjuvant hormone therapy influences the prognosis of patients with organ confined prostate cancer treated by radical prostatectomy...
  16. pmc Bioavailability of diclofenac potassium at low doses
    Burkhard Hinz
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nurnberg, Fahrstrasse 17, D 91054 Erlangen, Germany
    Br J Clin Pharmacol 59:80-4. 2005
    ..However, given the considerable first-pass metabolism of diclofenac, the degree of absorption of diclofenac-K at low doses remained to be determined. The aim of this study was to determine the bioavailability of low-dose diclofenac-K...